A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2019
Price : $35 *
At a glance
- Drugs NEO-PV 01 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 28 Sep 2019 Results assessing personalized neoantigen-targeting vaccines for high-risk melanoma, presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
- 25 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2020.
- 25 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.